NCT06159842View on ClinicalTrials.gov

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 8, 2023

Primary Completion Date

September 11, 2024

Study Completion Date

November 13, 2024

Conditions
Facial Cutaneous Squamous Cell Carcinoma in Situ
Interventions
COMBINATION_PRODUCT

Aminolevulinic Acid 20% Topical Solution with Blue Light

Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.

Trial Locations (1)

33180

Center for Clinical and Cosmetic Research, Aventura

All Listed Sponsors
collaborator

Sun Pharmaceutical Industries Limited

INDUSTRY

lead

The Center for Clinical and Cosmetic Research

OTHER